RE-BVS – Piemonte Repository

Sfoglia per AUTORE
MIGLIORINO MR
Collezione AO Ordine Mauriziano

Items : 6

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.

2022
AO Ordine Mauriziano

Cortellini A; Giusti R; Filetti M; Citarella F; Adamo V; Santini D; Buti S; Nigro O; Cantini L; Di Maio M; Aerts JGJV; Bria E; Bertolini F; Ferrara MG; Ghidini M; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Mazzoni F; Antonuzzo L; Gelibter A; Marchetti P; Chiari R; Macerelli M; Rastelli F; Della Gravara L; Gori S; et alii...

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.

2021
AO Ordine Mauriziano

Adamo V; Russo A; Metro G; De Filippis M; Simona C; Natalizio S; Migliorino MR; Landi L; Ricciardi S; Minuti G; Buti S; Nigro O; Cantini L; Russano M; Citarella F; Bracarda S; Zoratto F; Filetti M; Mansueto G; De Tursi M; Gori S; Rocco D; Chiari R; Rastelli F; Targato G; Gelibter A; Signorelli D; Mazzoni F; De Toma A; et alii...

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.

2021
AO Ordine Mauriziano

Addeo A; Banna GL; Spinelli GP; Russo A; Adamo V; Metro G; Olmetto E; Tabbò F; Ricciardi S; Migliorino MR; Minuti G; Landi L; Bisonni R; Tuzi A; Follador A; Siringo M; Gelibter A; Signorelli D; De Toma A; Garassino MC; Russano M; Mazzoni F; Citarella F; Filetti M; Zoratto F; Mansueto G; Di Marino P; De Tursi M; Gori S; et alii...

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. in Journal for immunotherapy of cancer / J Immunother Cancer. 2021 Apr;9(4):e002421. doi: 10.1136/jitc-2021-002421.

2021
AO Ordine Mauriziano

Bironzo P; Metro G; Passiglia F; Migliorino MR; Ricciardi S; Landi L; Minuti G; Bordi P; Tuzi A; Cantini L; Russano M; Citarella F; Santini D; Filetti M; Zoratto F; Mansueto G; Di Marino P; Grassadonia A; Michele T; Inno A; Della Gravara L; Rocco D; Chiari R; Rastelli F; Macerelli M; Marchetti P; Siringo M; Gelibter A; Signorelli D; et alii...

First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023. Epub 2020 Mar 25.

2020
AO Ordine Mauriziano

Facchinetti F; Mazzaschi G; Barbieri F; Passiglia F; Mazzoni F; Berardi R; Proto C; Cecere FL; Pilotto S; Scotti V; Rossi S; Del Conte A; Vita E; Bennati C; Ardizzoni A; Cerea G; Migliorino MR; Sala E; Camerini A; Bearz A; De Carlo E; Zanelli F; Guaitoli G; Garassino MC; Ciccone LP; Sartori G; Toschi L; Dall'Olio FG; Landi L; et alii...

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2017 Sep;111:30-37. doi: 10.1016/j.lungcan.2017.06.009. Epub 2017 Jun 16.

2017
AO Ordine Mauriziano

Gobbini E; Galetta D; Tiseo M; Graziano P; Rossi A; Bria E; Di Maio M; Rossi G; Gregorc V; Riccardi F; Scotti V; Ceribelli A; Buffoni L; Delmonte A; Franchina T; Migliorino MR; Cortinovis D; Pisconti S; Bordi P; Catino A; Maiello E; Arizio F; Novello S;